Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine

Journal of Pediatrics

Volumn 136, Issue 2, 2000, Pages 168-175

  Belshe, Robert B ^a   Gruber, William C ^b   Mendelman, Paul M ^b   Cho, Iksung ^b   Reisinger, Keith ^b   Block, Stan L ^b   Wittes, Janet ^b   Iacuzio, Dominick ^b   Piedra, Pedro ^b   Treanor, John ^b   King, James ^b   Kotloff, Karen ^b   Bernstein, David I ^b   Hayden, Frederick G ^b   Zangwill, Ken ^b   Lihan, Yan ^b   Wolff, Mark ^b  

^a S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033913482     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(00)70097-7     Document Type: Article

References (26)

1. 1. Glezen WP, Paredes A, Taber LH. Influenza in children: relationship to other respiratory viruses. JAMA 1980; 243:1345-9.
2. 2. Wright PF, Thompson T, Karzon DT. Differing virulence of H1N1 and H3N2 influenza strains. Am J Epidemiol 1980;112:814-9.
3. 3. Fox TP, Cooney MK, Hall CE, Foy HM. Influenza virus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am J Epidemiol 1982;116:228-42.
4. 4. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997;46:1-9.
5. 5. Maassab HF, Heilman CA, Herlocher ML. Cold-adapted influenza viruses for use as live vaccines for man. Adv Biotechnol Process 1990;14:203-42.
6. 6. Couch RB. Advances in influenza virus vaccine research. Ann New York Acad Sci 1993;685:803-12.
7. 7. Clancy RL. Mucosal vaccines for the prevention of influenza. Drugs 1995; 50:587-94.
8. 8. Belshe RB. A review of attenuation of influenza viruses by genetic manipulation. Am J Respir Crit Care Med 1995;152:S72-5.
9. 9. Maassab HF. Biologic and immunologic characteristics of cold-adapted influenza virus. J Immunol 1969;102:728-32.
10. 10. Cox NJ, Maassab HF, Kendal AP. Comparative studies of wild-type and cold-mutant (temperature-sensitive) influenza viruses: nonrandom reassortment of genes during preparation of live virus vaccine candidates by recombination at 25E between recent H3N2 and H1N1 epidemic strains and cold-adapted A/Ann Arbor/6/10. Virology 1979;97:190-4.
11. 11. Maassab HF, DeBorde DC. Characterization of an influenza A host range mutant. Virology 1983;130:342-50.
12. 12. Maassab HF, Kendal AP, Abrams GD, Monto AS. Evaluation of cold-recombinant influenza virus vaccine in ferrets. J Infect Dis 1982;146:780-90.
13. 13. Donabedian AM, DeBorde DC, Maassab HF. Genetics of cold-adapted B/Ann Arbor/1/66 influenza virus reassortants: the acidic polymerase (PA) protein gene confers temperature sensitivity and attenuated virulence. Microb Pathog 1987;3:97-108.
14. 14. Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998;338:11405-12.
15. 15. The 1995-96 WHO Influenza Reagent Kit for the Identification of Influenza Isolates [distributed by WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza, Centers for Disease Control and Prevention]. Atlanta (GA): Centers for Disease Control and Prevention; 1995. Appendix A, p. 15-9.
16. 16. COSTART: coding symbols for thesaurus of adverse reaction terms. 5th ed. Rockville (MD): Food and Drug Administration; 1995.
17. 17. SAS, Version 6.12, 1996. Cary (NC): SAS Institute Inc; 1996.
18. 18. Mathematical statistics. Oakland (CA): Holden-Day, Inc; 1977. p. 288.
19. 19. Update: influenza activity - United States, 1997-98 season. MMWR Morb Mortal Wkly Rep 1998;47:36-8.
20. 20. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1998;47:1-26.
21. 21. Update: influenza activity - United States, 1997-98 season. MMWR Morb Mortal Wkly Rep 1998;47:196-200.
22. 22. Influenza A - Florida and Tennessee, July-August 1998, and virologic surveillance of influenza, May-August 1998. MMWR Morb Mortal Wkly Rep 1998;47:756-9.
23. 23. Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, Belshe RB, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999;282: 137-44.
24. 24. Edwards KM, Dupont WD, Westrich MK, Plummer WD Jr, Palmer PS, Wright PF. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994;169:68-76.
25. 25. Wright PF, Karzon DT. Live attenuated influenza vaccines. Prog Med Virol 1987;34:70-88.
26. 26. Wright PF, Okabe N, McKee KT Jr, Maassab HF, Karzon DT. Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J Infect Dis 1982;146:71-9.